Mirimus
Mirimus provides high-quality animal and cell models for in vivo studies, specializing in RNAi and CRISPR/Cas9 technologies, and develops 3D tissue cultures from iPSCs. The company has been recognized for its innovative contributions, including winning the XPRIZE Rapid COVID Testing Competition and developing RNAi-based treatments for liver diseases.
Overview of Mirimus
Mirimus is a biotechnology company that provides high-quality animal and cell models for critical in vivo studies. Founded in 2010 by scientists from Cold Spring Harbor Laboratory, the company is located at 760 Parkside Avenue, Suite 206, Brooklyn, NY 11226. Mirimus specializes in innovative techniques such as RNAi and CRISPR/Cas9 to customize mouse and rat models for drug discovery and target validation.
RNAi and CRISPR/Cas9 Technology
Mirimus customizes RNAi and CRISPR/Cas9 mouse and rat models with potent, reversible gene silencing capabilities. These models are crucial for drug discovery and target validation. The company offers shRNA validation services using a functional Sensor reporter assay to identify top-performing shRNAs and develop artificial microRNAs (amiRNAs) with enhanced processing and specificity. This allows for the rapid and scalable study of gene function in mice using conditional RNA interference.
3D Tissue Culture Development
Mirimus develops clinically relevant 3D tissue cultures from induced pluripotent stem cells (iPSCs). These 3D cell cultures mimic human organ architecture, physiology, and disease states, bridging the gap between preclinical and clinical studies. They offer increased predictability of preclinical research outcomes, cost-effectiveness, and quicker design times compared to animal models. The company’s organoids provide a more accurate representation of the natural environment in the organism compared to traditional 2D cell cultures.
COVID-19 Surveillance and Testing
Mirimus played a significant role in COVID-19 surveillance and testing. The company developed the SalivaClear Pooled Testing Platform, which was used in partnerships with St. John's Athletics and Eckerd College for the testing of students and staff. Mirimus was a Grand Prize Winner of the XPRIZE Rapid COVID Testing Competition, highlighting their contribution to fighting the COVID-19 pandemic.
Collaborations and Partnerships
Mirimus has formed strategic collaborations to advance its research and development efforts. The company partnered with NYU Tandon scientists to produce new wearable health microchips and established a partnership with Biogen to develop RNAi-based therapeutics for neurological diseases. Mirimus also partnered with St. John's Athletics and Eckerd College for COVID-19 surveillance testing.